Image de couverture de livre

Patient Plasma‐Induced Neutrophil Dysfunction Is Associated With Infection Risk and Mortality in Patients With Acute Decompensation of Cirrhosis

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Supachaya Sriphoosanaphan, Jane Macnaughtan, Haw Lu, Rohit Sawhney, Qianwen Zhao, Lin Su, Rocio Gallego‐Duran, Emmanuel Wey, Nathan Davies, Rajeshwar P. Mookerjee, Rajiv Jalan
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation
par: Lucie Simonis, et autres
Publié: (2025)

Unstable Recompensation: An Intermediate Subtype in Patients With HBV ‐Related Decompensated Cirrhosis
par: Shuai Xia, et autres
Publié: (2025)

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID‐LSM Model
par: Luis Calzadilla Bertot, et autres
Publié: (2025)

Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
par: Yuki Utakata, et autres
Publié: (2026)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation
par: Thanawin Pramotedham, et autres
Publié: (2026)

Letter: Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
par: Zhanbo Qu
Publié: (2026)

Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation
par: David Tornai, et autres
Publié: (2025)

Editorial: Redefining Decompensation in Cirrhosis—More Than an Academic Playground? Authors' Reply
par: Lucie Simonis, et autres
Publié: (2025)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation. Authors' Reply
par: Mary Yue Wang, et autres
Publié: (2026)

Mortality of Acute Kidney Injury in Cirrhosis: A Systematic Review and Meta‐Analysis of Over 5 Million Patients Across Different Clinical Settings
par: Vasileios Lekakis, et autres
Publié: (2024)

Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease
par: Soroor Owrangi, et autres
Publié: (2024)

Editorial: ABID‐LSM–A Promising Model for Predicting Decompensation Risk in MASLD Cirrhosis
par: Eduardo Vilar‐Gomez, et autres
Publié: (2025)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis
par: Stephanie Tsai, et autres
Publié: (2025)

Statin Therapy Independently Reduces Mortality and Liver Complications in Patients With Cirrhosis: An Updated Systematic Review and Meta‐Analysis
par: Bernardo de Faria Moraes, et autres
Publié: (2026)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis. Authors' Reply
par: Bingqiong Wang, et autres
Publié: (2025)

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
par: Maral Amangurbanova, et autres
Publié: (2024)

Lymphocyte‐to‐Monocyte Ratio as a Predictor of Recompensation in Patients With Decompensated Primary Biliary Cholangitis
par: Huiying Lin, et autres
Publié: (2025)

Barriers to Medical Care Are Frequently Reported by Patients With Cirrhosis
par: William Chai, et autres
Publié: (2025)

Non‐selective beta‐blocker is associated with reduced mortality in critically ill patients with cirrhosis: A real‐world study
par: Rahul Kumar, et autres
Publié: (2024)

Network Meta‐Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction‐Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution
par: Matheus Souza, et autres
Publié: (2026)

Timely Follow‐Up After a First Diagnosis of Cirrhosis is Associated With Reduced Mortality but No Impact on Rehospitalisations: A Population‐Based Cohort of 8852 Patients
par: Max S. Schechter, et autres
Publié: (2024)

Editorial: Linking Patients With Cirrhosis to Clinical Care—The Hurdles and Way Forward
par: Jimmy Che‐To Lai, et autres
Publié: (2026)

Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
par: Donghee Kim, et autres
Publié: (2025)

Letter: Attempted Validation of Villin‐1 as a Gut Barrier Marker in Decompensated Cirrhosis—Potential Confounding by Tubular Injury and Aetiology. Authors' Reply
par: David Tornai, et autres
Publié: (2026)

Editorial: Polypharmacy in MASLD—An Overlooked Epidemic Disproportionately Affecting Women and Patients With Cirrhosis
par: Mary Yue Wang, et autres
Publié: (2025)

Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology
par: Yu Shi, et autres
Publié: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’
par: Sai Kiran Kuchana, et autres
Publié: (2026)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
par: Yuki Utakata, et autres
Publié: (2026)

Emerging Trends in Patients Hospitalised With Cirrhosis—Aetiologies, Complications and Outcomes Compared to Other Chronic Health Conditions
par: Julian Pohl, et autres
Publié: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
par: Christian Labenz, et autres
Publié: (2026)

Correction to ‘Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon’
Publié: (2025)

Spontaneous Bacterial Peritonitis Is Associated With High Mortality, Which Interacts With Antibiotic Prophylaxis in a National Cirrhosis Cohort
par: Scott Silvey, et autres
Publié: (2025)

Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial
par: Mazen Noureddin, et autres
Publié: (2025)

Air Pollution Associated With Mortality Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues
par: Tyng‐Yuan Jang, et autres
Publié: (2025)

Editorial: Decoding ACLF—Sub‐Phenotyping to Advance Precision Medicine in Acute‐On‐Chronic Liver Failure
par: Amy Sangam, et autres
Publié: (2024)

Long‐Term Follow‐Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss
par: Simon J. Hume, et autres
Publié: (2025)

Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality
par: Donghee Kim, et autres
Publié: (2025)

Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low‐Level Viraemia
par: Paul Y. Kwo, et autres
Publié: (2026)

Epidemiology, Predictors of Antimicrobial Resistance and Empiric Treatment Strategies for Spontaneous Bacterial Peritonitis in Cirrhosis: A Multicentre SBP ‐ INDIA Study
par: Nipun Verma, et autres
Publié: (2026)

Editorial: Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients With Metabolic Dysfunction—Do Existing Scores Clear the Bar?
par: Danny Con
Publié: (2025)